Please assess the completion status of the following clinical trial:

Trial Title: Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 70 years of age~* Patients with ECOG Performance Status of ≤ 2~* Patients with a documented unequivocal diagnosis of AML according to WHO 2008 classification (\>20% blasts in the bone marrow), excluding M3 (acute promyelocytic leukemia).~* Patients with a documented FLT3 ITD mutation, determined by local laboratory for eligibility (historical tissue will be requested for central analysis confirmation)~* Patients who undersent allogeneic HSCT in CR1 from a matched related or matched unrelated donor. All of the following criteria had to be met: HLA typing to include available 8/8 or 7/8 allele HLA matched donor (at A,B,C, DRB1) Single allelic mismatch allowed~* Patients who had received a conditioning regimen which included one of the following:~Busulfan/Fludarabine (Bu/Flu) Busulfan (16 mg/kg PO or 12.8 mg/kg IV) Fludarabine (120-180 mg/m2) Fludarabine / Melphalan (Flu/Mel) Fludarabine (120-180 mg/m2) Melphalan (≤ 150 mg/m2) Busulfan/Cyclophosphamide (Bu/Cy) Busulfan (16 mg/kg PO or 12.8 mg/kg IV) Cyclophosphamide (120 mg/kg) Cyclophosphamide/Total Body Irradiation (Cy/TBI) Cyclophosphamide (120 mg/kg) TBI (1200-1420 cGy)~• Recovery of counts by day 42 and was able to start midostaurin by day 60 post-HSCT (first dose of midostaurin to start no earlier than 28 days post-HSCT); ANC \>1000µL, platelets ≥20,000 without platelet transfusion~Exclusion Criteria:~Patients eligible for this study must not have met any of the following criteria:~* Patients who failed prior attempts at allogeneic HSCT~* Patients who had received an autologous transplant~* Patients with Acute GVHD Grade III-IV~* Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.~* Impaired cardiac function including any of the following:~  * Screening ECG with a QTc \> 450 msec. If QTc \> 450 and electrolytes were not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc.~ * Patients with congenital long QT syndrome~ * History or presence of sustained ventricular tachycardia~ * Any history of ventricular fibrillation or torsades de pointes~ * Bradycardia defined as HR. \< 50 bpm~ * Right bundle branch block + left anterior hemiblock (bifascicular block)~ * Patients with myocardial infarction or unstable angina \< 6 months prior to starting study~ * Congestive Heart Failure NY Heart Association class III or IV~ * Patients with an ejection fraction \< 45% assessed by MUGA or ---ECHO within 28 days prior to starting study cycle 1 (of midostaurin or control group)~* Patients with any pulmonary infiltrate including those suspected to be of infectious origin (unless resolves to ≤ Grade 1 within screening timeframe)~* Patient required treatment with strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers other than those required for GVH or infection prophylaxis or treatment~Pregnant or nursing (lactating) women, or women of child-bearing potential, must have used highly effective methods of contraception during dosing and for 30 days after treatment completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care with Midostaurin (Type: EXPERIMENTAL): Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients received standard of care alone in the post SCT setting

Based on this trial design, predict the completion outcome and termination type (if applicable).